SynthesisCancer medicine2024

Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.

Ming-Han Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.